AstraZeneca PLC saw its stock gain ground after the company released second-quarter results that exceeded analyst expectations on the core earnings per share line. The shares rose 1.6% to 12,871p after the group reported core EPS of $2.63, ahead of the market consensus of $2.48, while revenue was roughly $15.4 billion, broadly in line with forecasts.
The results were driven by strength in the oncology franchise, notably the breast cancer therapy Enhertu, together with contributions from the rare disease portfolio. Management said these revenue streams more than offset the impact of Farxiga losing exclusivity in the United States.
Management kept full-year 2026 guidance intact. Chief Executive Pascal Soriot said the company remains "on track to deliver our $80 billion total revenue ambition, which assumes successes and setbacks."
Investors received an additional boost from a clinical development update announced on July 26. AstraZeneca said its antibody-drug conjugate sonesitatug vedotin produced a statistically significant improvement in overall survival in the CLARITY-Gastric01 Phase III trial for CLDN18.2-positive advanced gastric cancer, meeting the trial's dual primary endpoint. That result provided a welcome recovery in pipeline sentiment after a run of disappointing trial outcomes.
Those prior setbacks included the failure of Ultomiris in a Phase III HSCT-TMA study and the earlier miss in the Wainua CARDIO-TTRansform cardiovascular trial. Those negative clinical reads had placed pressure on the stock in recent weeks, and the new gastric cancer result helped to reverse some of that damage.
The market environment was also favorable to the share move. The FTSE 100 was set for a strong open during a busy UK earnings week in which AstraZeneca was the most prominent reporter. U.S. equity markets provided a supportive backdrop as well, with the S&P 500 up 0.9% and the Nasdaq rising 1.4%, reflecting broader risk appetite across developed markets.
Taken together, the earnings beat that highlighted the resilience of AstraZeneca's diversified commercial base, the Phase III gastric cancer success and a constructive global market mood gave investors reason to push the stock higher. The shares, however, remain below their 52-week high of 15,730p, indicating there is room for further recovery as pipeline doubts are gradually addressed.
Summary
AstraZeneca outperformed on core EPS in Q2 2026, maintained full-year guidance, and reported a positive Phase III overall survival result for sonesitatug vedotin in CLDN18.2-positive advanced gastric cancer. The commercial strength from oncology and rare disease offerings offset the revenue pressure from Farxiga's loss of exclusivity in the U.S. Market conditions in the U.K. and U.S. supported the share gain.
Key points
- AstraZeneca reported core EPS of $2.63 for Q2 2026 versus a consensus of $2.48, with revenue around $15.4 billion.
- Oncology, led by Enhertu, and the rare disease portfolio were the main growth drivers that offset Farxiga's U.S. exclusivity loss.
- Positive Phase III overall survival results for sonesitatug vedotin in CLDN18.2-positive advanced gastric cancer improved pipeline sentiment after recent trial setbacks.
Risks and uncertainties
- Pipeline volatility - recent trial failures such as Ultomiris in a Phase III HSCT-TMA trial and the Wainua CARDIO-TTRansform miss have previously weighed on the stock, indicating future trial outcomes remain a material risk to sentiment.
- Loss of exclusivity - Farxiga's loss of U.S. exclusivity has negatively impacted revenues and remains a headwind for the cardiovascular/diabetes portfolio.
- Share price recovery - although the stock rose, it still trades well below its 52-week high of 15,730p, suggesting limited near-term upside until pipeline concerns further abate.
Note: This article focuses on the Q2 2026 results and related corporate updates as reported. It does not include additional external analysis or commentary beyond the information provided in the company announcements and market moves cited above.